H.C. Wainwright slashes Capricor stock price target to $24 on FDA rejection

Capricor Therapeutics (NASDAQ:CAPR) shares declined nearly 23% after the FDA issued a Complete Response Letter (CRL) for its deramiocel Biologics License Application, citing insufficient efficacy evidence and Chemistry, Manufacturing, and Controls (CMC) issues. Despite the regulatory setback, analysts like H.C. Wainwright (who lowered its price target to $24 but maintained a Buy rating) and B.Riley remain optimistic, as Capricor plans to resubmit with topline data from its Phase 3 HOPE-3 trial, expected in Q3 2025, and engage the FDA in a Type A meeting. The company's strong financial position, evidenced by more cash than debt and a healthy current ratio, is expected to support its navigation of this challenge.

Analysis

Capricor Therapeutics has experienced a significant regulatory setback with the FDA's issuance of a Complete Response Letter (CRL) for its deramiocel Biologics License Application, precipitating a nearly 23% decline in its stock price. The rejection was based on insufficient evidence of effectiveness from the OLE HOPE-2 trial and outstanding Chemistry, Manufacturing, and Controls (CMC) issues. The company's strategic pivot now centers on its ongoing Phase 3 HOPE-3 trial, with topline data expected in Q3 2025, which it plans to use for a resubmission to the FDA. Despite the delay, analyst sentiment, while cautious, remains supportive; H.C. Wainwright maintained a 'Buy' rating despite a severe price target reduction to $24.00 from $77.00, and B.Riley initiated coverage with a 'Buy'. This optimism is underpinned by the company's robust financial health, characterized by more cash than debt and a strong current ratio of 6.55, suggesting it is well-capitalized to navigate the extended development and review timeline.

Key Decisions for Investors

• Investors should re-evaluate positions in light of the significantly delayed timeline, as the next key catalyst—topline data from the HOPE-3 trial—is not expected until Q3 2025, making this a long-duration, high-risk holding.
• The company's strong financial position is a key mitigating factor, but it is critical to monitor cash burn rates to ensure it can sustain operations through the extended regulatory process without requiring dilutive financing.
• Pay close attention to disclosures from the upcoming Type A meeting with the FDA, as its outcome will provide crucial clarity on the agency's specific requirements and the viability of Capricor's resubmission plan.